The ASCO Post

3 days ago | ascopost.com | Leah Lawrence

ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials comparing SLNB alone against SLNB with complete axillary lymph node dissection (ALND) and two trials comparing SLNB against no axillary surgery.2 “Several decades ago, we felt that we needed to know...

3 days ago | ascopost.com | Chase Doyle

Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented during the 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting.1 Primary results from the phase II multicenter POWER trial showed that this preoperative window allowed patients to gauge...

1 week ago | ascopost.com | Caroline Helwick

According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory to other therapies (Abstract S100).

1 week ago | ascopost.com | Chase Doyle

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to hydroxyurea, according to data from the phase III SURPASS-ET trial presented at the European Hematology Association (EHA) 2025 Congress (Abstract S102).

1 week ago | ascopost.com | Chase Doyle

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the European Hematology Association (EHA) 2025 Congress (Abstract S230).